Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review
ConclusionPaediatric pictorial PROMs offer child-friendly tools for assessing HRQoL for application with children who find reading and understanding text-based PROMs challenging. There is some evidence that pictorial PROMs facilitate self-report in this population and improve measurement properties compared to text-only PROMs. Further research is needed to develop, validate, and test paediatric pictorial PROMs, with an emphasis on including children from the inception in the co-design process. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 13, 2024 Category: Health Management Source Type: research
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review
ConclusionsThis study provides an overview of current QoL instruments used in economic evaluations of sleep with respect to their content coverage. A combination of generic and sleep-specific instruments with broader ICF content coverage is recommended for such evaluations. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 10, 2024 Category: Health Management Source Type: research
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression
ConclusionsWhile each instrument showed strong performance in some areas, careful consideration of the choice of instrument is advised, as this may differ dependent on the intended use of the instrument, and the age, gender and type of mental health condition of the population in which the instrument is being used.Trial RegistrationANZCTR —ACTRN12621000657820. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 8, 2024 Category: Health Management Source Type: research
Incorporating Real Option Value in Valuing Innovation: A Way Forward
ConclusionThe minimal modeling approach and the checklist developed in this paper simplifies and standardizes the estimation and reporting of ROV in value assessment. Systematically including and reporting ROV in value assessment will minimize bias and improve transparency, which will help improve the credibility of ROV research and acceptance by stakeholders. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 4, 2024 Category: Health Management Source Type: research
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA
ConclusionsOver 3 years, the estimated cumulative per patient cost of mosunetuzumab is lower than most available newer therapies, resulting in a small increase in the budget after its formulary adoption for the treatment of relapsed or refractory follicular lymphoma. (Source: PharmacoEconomics)
Source: PharmacoEconomics - February 1, 2024 Category: Health Management Source Type: research
Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2 –4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL)
ConclusionThe CHU9D was found to be valid and reliable to measure health-related quality-of-life in children aged 2 –4 years, although with relatively low test–retest reliability in some dimensions. Further development and validation work is warranted. (Source: PharmacoEconomics)
Source: PharmacoEconomics - January 27, 2024 Category: Health Management Source Type: research
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L
ConclusionsThis study demonstrates that choice of proxy perspective may have an impact on the problems reported on HRQoL dimensions and EQ VAS scores. However, in this community-based sample of generally healthy children, no significant difference was observed in the inter-rater agreement for child-self and proxy preference-weighted EQ-5D-Y-3L values based on proxy perspectives. While this suggests that preference-weighted data are not sensitive to the choice of perspective, these findings may differ for different HRQoL instruments and for alternative value sets with different properties. (Source: PharmacoEconomics)
Source: PharmacoEconomics - January 27, 2024 Category: Health Management Source Type: research
Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2 –4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL)
ConclusionThe CHU9D was found to be valid and reliable to measure health-related quality-of-life in children aged 2 –4 years, although with relatively low test–retest reliability in some dimensions. Further development and validation work is warranted. (Source: PharmacoEconomics)
Source: PharmacoEconomics - January 27, 2024 Category: Health Management Source Type: research
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L
ConclusionsThis study demonstrates that choice of proxy perspective may have an impact on the problems reported on HRQoL dimensions and EQ VAS scores. However, in this community-based sample of generally healthy children, no significant difference was observed in the inter-rater agreement for child-self and proxy preference-weighted EQ-5D-Y-3L values based on proxy perspectives. While this suggests that preference-weighted data are not sensitive to the choice of perspective, these findings may differ for different HRQoL instruments and for alternative value sets with different properties. (Source: PharmacoEconomics)
Source: PharmacoEconomics - January 27, 2024 Category: Health Management Source Type: research
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review
ConclusionsBased on reported willingness to pay thresholds for each setting, most CEA studies concluded that screening for FH compared with no screening was cost-effective, regardless of the screening strategy. Cascade screening resulted in the largest health benefits per person tested. (Source: PharmacoEconomics)
Source: PharmacoEconomics - January 24, 2024 Category: Health Management Source Type: research
